ABBOTT LABORATORIES — Director's Dealing 2025

Mar 4, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2025-03-01

Reporting Person: Shroff Eric (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	32532	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$75.90	2029-02-21	Common Shares (26971)		Direct
Option (right to buy)	$87.72	2030-02-20	Common Shares (29020)		Direct
Option (right to buy)	$124.04	2031-02-18	Common Shares (20045)		Direct
Option (right to buy)	$117.58	2032-02-17	Common shares (20404)		Direct
Option (right to buy)	$106.24	2033-02-16	Common shares (13056)		Direct
Option (right to buy)	$116.98	2034-02-20	Common shares (13250)		Direct
Option (right to buy)	$135.42	2035-02-24	Common shares (27227)		Direct

Footnotes

F1: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,352 on February 17, 2024, 4,352 on February 17, 2025, and 4,352 on February 17, 2026.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,416 on February 21, 2025, 4,417 on February 21, 2026, and 4,417 on February 21, 2027.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,075 on February 25, 2026, 9,076 on February 25, 2027, and 9,076 on February 25, 2028.